Literature DB >> 10553818

Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs.

R J McCarthy1, K J Tuman, C O'Connor, A D Ivankovich.   

Abstract

UNLABELLED: We evaluated the effect of aprotinin, administered before the onset of acute regional myocardial ischemia, on reversible contractile dysfunction induced by ischemia and reperfusion in pentobarbital-anesthetized dogs. Animals were randomized to receive either aprotinin 30,000 kallikrein inactivator units (KIU)/kg and 7000 KIU x kg(-1) x hr(-1) (n = 8) or equivalent volumes of 0.9% sodium chloride (n = 7) IV 60 min before a 15-min interruption of circumflex coronary artery blood flow and then reperfusion. There were no intra- or intergroup differences in hemodynamic variables or regional myocardial mechanics (sonomicrometry) before onset of ischemia. Immediately before reperfusion, systolic dysfunction characterized by significantly decreased percent systolic shortening was present in the circumflex coronary artery area of both study groups. After reestablishment of perfusion, aprotinin animals had preserved percent systolic shortening whereas saline animals exhibited regional systolic dysfunction. Regional myocardial contractility as assessed by the slope Mw of the preload recruitable stroke work relation was preserved during reperfusion in animals who received aprotinin but depressed in the control group. We conclude that functional recovery from myocardial ischemia-reperfusion injury at normothermia is improved by IV administration of aprotinin before the onset of acute regional myocardial ischemia in physiologically intact dogs. IMPLICATIONS: Administration of clinically relevant doses of aprotinin IV before the onset of regional myocardial ischemia, in contrast to control conditions, preserved regional systolic function and contractility at baseline values after reestablishment of myocardial perfusion in dogs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553818

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition.

Authors:  Michael O Griffin; Miki Jinno; Lindsey A Miles; Francisco J Villarreal
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

2.  Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy.

Authors:  Daryl L Reust; Jennifer A Dixon; Richard A McKinney; Risha K Patel; William T Rivers; Rupak Mukherjee; Robert E Stroud; Karen Madden; Kevin Groves; Milind Rajopadhye; Scott T Reeves; James H Abernathy; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

3.  Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I.

Authors:  Michel J Sabbagh; J Michael Looper; Juozas A Zavadzkas; Robert E Stroud; Rachael L Ford; William T Rivers; Christine N Koval; Matthew D McEvoy; Scott T Reeves; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2008-10       Impact factor: 3.105

4.  Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion.

Authors:  Matthew D McEvoy; Anna-Greta Taylor; Juozas A Zavadzkas; Ira M Mains; Rachael L Ford; Robert E Stroud; Laura B Jeffords; Christy U Beck; Scott T Reeves; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

5.  Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model.

Authors:  Matthew D McEvoy; Michel J Sabbagh; Anna Greta Taylor; Juozas A Zavadzkas; Christine N Koval; Robert E Stroud; Rachael L Ford; Julie E McLean; Scott T Reeves; Rupak Mukherjee; Francis G Spinale
Journal:  Anesth Analg       Date:  2009-02       Impact factor: 5.108

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.